Galectin Therapeutics Inc expected to post a loss of 17  cents a share - Earnings Preview

Galectin Therapeutics

15/05/2021 03:51

* Galectin Therapeutics Inc  GALT.OQ   GALT.O  is expected
to show a no change in quarterly revenue when it reports
results on May 14 (estimated) .
​* Refinitiv's mean analyst estimate for Galectin Therapeutics
Inc is for a loss of 17 cents per share. For the same quarter
last year, the company reported a loss of 6 cents per share.
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 1 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
* The mean earnings estimate of analysts was unchanged in the
last three months. ​
* Wall Street's median 12-month price target for Galectin
Therapeutics Inc is $14​, about 69.8% above​ its last closing
price of $4.23. ​​​
* Previous quarterly performance (using preferred earnings
measure in US dollars). ​
 QUARTER       STARMINE    REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        SMARTESTIM  IBES                 MET,    SE %
               ATE®        ESTIMATE             MISSED  
 Dec. 31 2020              -0.16      -0.13     Beat    18.8
 Sep. 30 2020  -0.14       -0.14      -0.10     Beat    28.6
 Jun. 30 2020              -0.09      -0.11     Missed  -15.8​
 Mar. 31 2020  -0.09       -0.09      -0.06     Beat    33.3
 Dec.          ​           -0.06      -0.12     Missed  -100​
 31​ 2019​                                              
 Sep. 30 2019  -0.10       -0.08      -0.05     Beat    41.2​
 Jun. 30 2019  -0.12       -0.12      -0.06     Beat    50
 Mar. 31 2019  -0.15       -0.14      -0.20     Missed  -42.9
 This summary was machine generated May 15 at 02:51 GMT.  All
figures in US dollars unless otherwise stated